Press Releases

Zebrafish Disease Models: Accelerating Human Disease Studies and Biomedical Research

Microbiosci Offers Real-time PCR Kits to Support Research Applications in Viral Detection

CRISPR/Cas9 Platform Provides Accurate Gene Knockout Mouse Models for Immunology Research and Drug Discovery

Creative Bioarray Provides Cell Patterning Customization and Detection Services for Drug Screening

Creative Enzymes Offers Products to Support the Clinical and Research Use of Liver Function Evaluation

Creative Proteomics Cytokine Accelerates Your Project with Its Colony Stimulating Factor Detection Service

Pronalyse Unveils Insightful Metabolite Identification Services of Biopharmaceuticals

Creative Proteomics Has Optimized Pre-treatments and Assays for Different Types of Vitamins

Quinten Health closes its financing round to advance disease modeling platforms and virtual twins in real-world

QUINTEN HEALTH has announced that it has closed its financing round to advance disease modeling platforms and virtual twins in real-world.

The Harley Street Medical Area (HSMA) Healthcare Conference unites world-leading institutions to discuss the future of life science innovation in London

Harley Street Medical Area has announced its Healthcare Conference is taking place on Wednesday 19th October 2022.

DAMAN enters ambitious European precision medicine healthcare project

Daman Digital (DAMAN), a digital healthcare partner based in Denmark, has announced its part in the ambitious European precision medicine healthcare project, SQUEEZE.

BioIVT Launches GMP-grade VivoSTART Leukopaks for Cell and Gene Therapy Manufacturing

VivoSTART GMP-grade leukopaks complement BioIVT’s GMP-grade human AB serum, providing a complete solution for advanced therapy development.

VERICHEM OFFERS CLINICAL REFERENCE MATERIALS FOR THE CALIBRATION VERIFICATION TESTING OF LACTATE ASSAYS

VERICHEM LABORATORIES now offers a liquid stable and ready-to-use set of clinical reference materials for use with the clinical testing of Lactate.

Tasso+™ Device Earns FDA 510(k) Class II Medical Device Clearance

Tasso announced that the U.S. FDA has cleared its Tasso+™ lancet as a Class II medical device.

BioIVT Acquires XenoTech, a Leading Provider of Products and Services for Preclinical Testing of New Drug Candidates

XenoTech specializes in providing ADME-Tox products and research services, in particular drug metabolism and pharmacokinetics (DMPK) and drug-drug interaction (DDI) studies.

Clinion - Platinum Sponsor for ISCR 3rd Autumn Conference 2022

Clinion is anticipating the world’s leading clinical research specialists to participate in the ISCR 3rd Autumn Conference, with the purpose of stepping into a brand-new era of clinical trial innovation! HICC, Novotel, Hyderabad, Telangana, India, 17 September 2022

BOC Sciences 2022 Free Webinar: Viral RNA Modifications and Implications for Novel Therapeutics

BOC Sciences grandly announced the schedule of a free webinar on September 19th, 2022, at 11:00 EDT, which is a laudable event centering on the hot spot of RNA research during the pandemic.

BOC Sciences August Promotion: Comprehensive Labeled Peptides with Stable Quality

As a pioneer in stable isotopic labeling chemistry, BOC Sciences develops a large variety of SIL compounds. Its promotion of labeled peptides, the increasingly used materials for convenient detection in research, is on the boil in August.

Cofactor Genomics Unveils New Data Showing Novel OncoPrism Diagnostic is Nearly Twice as Accurate as PD-L1 in Identifying Immunotherapy Responders

In clinical studies where OncoPrism was tuned to have the same sensitivity as PD-L1, Cofactor’s test reached 75% accuracy in predicting responders to immune checkpoint inhibitors, when compared to 42% accuracy for PD-L1. These interim results from nine healthcare systems show at similar sensitivity, OncoPrism has greater specificity and continues to be superior to single analyte approaches like PD-L1. The staggering improvement in prediction is based on OncoPrism’s Predictive Immune Modeling platform of multidimensional RNA models that capture health-related state, compounded with machine learning to better understand disease and predict therapy response

BioIVT Highlights ADME-Tox Research Advances at ISSX/MDO 2022

BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, is highlighting recent ADME-Tox research at the 13th International Meeting of the International Society for the Study of Xenobiotics (ISSX) and 24th International Symposium on Microsomes and Drug Oxidations (MDO). This conference will be held from September 11-14 at the Westin Seattle.